Pyrazine diazohydroxide (NSC 361456) sodium is an anti-tumor agent that forms DNA adducts via the reactive pyrazine diazonium ion. Pyrazine diazohydroxide sodium can be used for the study of renal cancer, colorectal cancer, melanoma and leukemia.

PTP1B-IN-33 is a PTP1B inhibitor with a human IC50 of 2.45 μM and over 20-fold selectivity for PTP1B over SHP2. PTP1B-IN-33 enhances π-Alkyl interaction with PTP1B to increase WPD loop closure degree. PTP1B-IN-33 can be used for the research of cancer, diabetes, autoimmune deficiency diseases.

P-SCN-Bn-NOTA is a metal chelator and molecular imaging probe precursor that allows radiolabeling with Ga-68. P-SCN-Bn-NOTA can be conjugated to CD70-specific molecules B3, B6, ABDB3 and ABDB6 to form NOTA-labeled derivatives. P-SCN-Bn-NOTA is applicable for preclinical PET/CT imaging of CD70-expressing tumors in NCG mouse PDX models. P-SCN-Bn-NOTA can be used in studies related to CD70-positive tumors.

PS1097 is a broad-spectrum antiviral inhibitor with a BVDV RdRp IC50 of 0.64 μM. PS1097 selectively reduces RTN3 protein levels, causes partial RTN3 mRNA reduction, and leaves other endoplasmic reticulum-resident proteins unaffected. PS1097 inhibits replication of Zika virus and multiple viruses that use the endoplasmic reticulum as a replication hub. PS1097 inhibits BVDV RdRp enzymatic activity and exerts activity against Bovine Viral Diarrhea Virus. PS1097 can be used for the research of zika virus infection, usutu virus infection, west nile virus infection, COVID-19, coxsackie b virus 5 infection, chikungunya virus infection, vaccinia virus infection.

PROTAC USP7 Degrader-2 (Compound D16) is an efficient and selective USP7 PROTAC degrader with a DC50 of 1.91 μM (in TE-12 cells). PROTAC USP7 Degrader-2 inhibits the migration of upper gastrointestinal tract (UGI) cancer cells and shows relatively weak anti-proliferative activity. PROTAC USP7 Degrader-2 can be used in the research of metastatic upper gastrointestinal cancer. (Pink: USP7 ligand ; Blue: Cereblon ligand ; Black: linker).

PROTAC HyTTD Degrader-1 (Compound B2) is a hydrophobic tag tethered degrader (HyTTD) targeting RET, as well as a degrader of the CCDC6-RET fusion protein. PROTAC HyTTD Degrader-1 induces the degradation of the CCDC6-RET fusion protein via the ubiquitin-proteasome pathway. PROTAC HyTTD Degrader-1 is applicable to the research of RET-driven cancers. (Pink: FLT3 and RET ligand ; Blue: Others ligand ; Black: linker ).

PROTAC EZH2 Degrader-37 (compound 16) is a PROTAC protein degrader targeting EZH2 with a target IC50 of 144 nM. PROTAC EZH2 Degrader-37 is applicable to lymphoma-related research. (Pink: Histone Methyltransferase ligand ; Blue: Cereblon ligand ; Black: linker).

PROTAC EZH2 Degrader-36 (compound 15) is a PROTAC protein degrader targeting EZH2 with a target IC50 of 16.00 nM.PROTAC EZH2 Degrader-36 applicable to lymphoma-related research. (Pink: Histone Methyltransferase ligand ; Blue: Cereblon ligand ; Black: linker).

PROTAC EZH2 Degrader-20 (compound 54) is an EZH2-target PROTAC degrader with antiproliferative activity and IC50 values of about 10 μM against lymphoma cells. PROTAC EZH2 Degrader-20 can be used for the research of lymphoma. (Pink: Histone Methyltransferase ligand ; Blue: Aminopeptidase ligand ; Black: linker).

PROTAC EZH2 Degrader-15 (compound 5) is an EZH2-targeting PROTAC. PROTAC EZH2 Degrader-15 functionally inhibits EZH2 methyltransferase activity. (Pink: EZH2 ligand ; Blue: Cereblon ligand ; Black: linker).

PROTAC EZH2 Degrader-10 (compound 1) is a PROTAC protein degrader targeting EZH2. PROTAC EZH2 Degrader-10 can be used for the research of cancer. (Pink: EZH2 ligand ; Blue: Cereblon ligand ; Black: linker).

PROTAC BRD3 degrader-1 (compound D072) is a potent and selective PROTAC BRD3 degrader. PROTAC BRD3 degrader-1 selectively degrades BRD3 in mice, leading to the downregulation of H3K18ac without affecting BRD2 or BRD4. PROTAC BRD3 degrader-1 reduces intraocular inflammation in the experimental autoimmune uveitis (EAU) mouse mode and inhibits proinflammatory microglia in both uveitis retina and LPS treated mouse microglia cell line BV2. PROTAC BRD3 degrader-1 can be used for uveitis research. (Pink: BRD3 ligand ; Blue: Cereblon ligand ; Black: linker).

Proquinazid is a Bcl-2 and PCNA modulator, oxidative stress inducer, genotoxin and apoptosis inducer. Proquinazid causes DNA damage and also triggers apoptosis by regulating pro-apoptotic and anti-apoptotic proteins.

PRMT5-MTA-IN-7 (Compound 14) is a selective PRMT5-MTA inhibitor. PRMT5-MTA-IN-7 exhibits KD values of PRMT5-MTA-IN-7 for PRMT5-MTA and PRMT5-SAM of 236 nM and 2.84 μM respectively, and the IC50 values of 4.08 and 13.6 μM respectively. PRMT5-MTA-IN-7 can selectively inhibit the proliferation of MTAP-deficient cancer cells. PRMT5-MTA-IN-7 can be used for the study of colon cancer.

PNA5 is a novel, blood-brain barrier permeable glycosylated angiotensin-(1-7) peptide and MasR agonist. PNA5 inhibits IL-7, increases IL-10. PNA5 inhibits ROS generation, decreases Iba-1 expression. PNA5 exhibits sustained cognitive protective effects. PNA5 rescues blunted cerebral functional hyperemia. PNA5 can be used in the research of inflammation-related brain diseases.

pKal-IN-1 (compound 13) is a plasma kallikrein (pKal) inhibitor. pKal-IN-1 can be used for the research of diabetic macular edema, diabetic retinopathy.

Piquindone (Ro 22-1319) is a potent antipsychotic agent. Piquindone binds to a D2 dopaminergic receptor subtype in a sodium-dependent manner. Piquindone can be used in the research of schizophrenia.

Picenadol (LY-150720) hydrochloride is an opioid mixed agonist-antagonist analgesic. Picenadol hydrochloride is an external racemic mixture, where its d-isomer (LY136596) is a potent μ-opioid receptor agonist, and the l-isomer (LY136595) is a weak μ-receptor competitive antagonist, which can inhibit the agonist effect and reduce the risk of dependence. Picenadol hydrochloride has anticholinergic activity.

Penisimplicissin is a funicone-like compound and antiviral agent. Penisimplicissin reduces the expression of AhR and viral nucleocapsid protein. Penisimplicissin improves the cell viability and morphological characteristics of CCoV-infected cells. Penisimplicissin inhibits CCoV infection. Penisimplicissin can be used in studies related to canine coronavirus infection.

PDE1-IN-12 (P78, the first compound in 12) is a PDE1 inhibitor. PDE1-IN-12 inhibits PDEl-mediated suppression of the dopamine D1 receptor intracellular pathway and can be used for narcolepsy.

PDE1-IN-11 (Compound 5cc) is an orally active and highly selective PDE1A1 inhibitor. PDE1-IN-11 increases intracellular cAMP and cGMP levels, activating the PKA-CREB and NO-cGMP-PKG signaling pathways, promoting osteoblast differentiation and bone formation, while suppressing osteoclastogenesis and bone resorption. PDE1-IN-11 is promising for research of postmenopausal osteoporosis (PMO) and other bone metabolism disorders.

PAT-347 sodium is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood.

PAT-078 is a type II autotaxin (ATX) inhibitor. PAT-078 mainly occupies the hydrophobic pocket of ATX, blocks the bottleneck region between the hydrophobic channel and the catalytic site, and does not interact with the zinc ion at the catalytic site.

PARP1-IN-56 (Compound RCY) is an I-labeled poly(ADP−ribose) polymerase (PARP1) inhibitor. PARP1-IN-56 can be radiolabeled with 211At or 125I for use as an α-emitting radiotherapeutic agent. PARP1-IN-56 can be used for the research of cancer.

P38α-IN-11 (Compound 16c) is a p38α inhibitor with a KD value of 586 nM. P38α-IN-11 can be used for research on cervical cancer.

p38 MAP Kinase-IN-2 (Compound 5) is a p38 MAP Kinase inhibitor. p38 MAP Kinase-IN-2 can be used for the research of cancer.

P2L-003 is a selective PAR2 antagonist with an IC50 of 0.62 μM in HT-29 cells. P2L-003 blocks PAR2-mediated Ca2+ mobilization without affecting PAR1, PAR4, or ATP-mediated signaling and dose-dependently suppresses the downstream MAPK signaling cascades, including ERK1/2 and p38 phosphorylation. P2L-003 can be used for colon cancer research.

OK-1035 is a selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 100 μM.

OH14 is a cellular FLICE-like inhibitory protein (cFLIP) inhibitor and TNF-related apoptosis-inducing ligand (TRAIL) sensitizer. OH14 selectively binds to the DED1 pocket of cFLIP, disrupting its recruitment to the TRAIL-death inducing signalling complex without affecting procaspase-8 recruitment to FADD, allowing procaspase-8 activation. OH14 promotes TRAIL-mediated apoptosis and impairs cell viability in breast cancer systems when combined with TRAIL. OH14 can be used for the research of breast cancer.

O-1812 is a selective CB1 ligand. O-1812 is also a very weak AMT inhibitor. O-1812 can be used in the research of chronic pain, migraines, and inflammation.